Review · United States
Tesamorelin
Reviewed on
Approval and product status
An FDA-approved product exists for a narrow indication
The two approved products are not interchangeable. Egrifta SV and Egrifta WR are approved, non-substitutable formulations with product-specific labeling. Tesamorelin sold or compounded outside those products is not automatically equivalent.
What was measured in people?
- Health results · Strong
- Phase 3 trials support visceral-adipose-tissue reduction in the labeled HIV population.
- Body changes · Strong
- The approved label characterizes IGF-1 response, exposure, and product-specific use.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
This prescription drug has benefits for a specific group and important monitoring requirements. No dosing, cycling, stacking, or performance-use guidance is provided.
Still unknown: These results do not establish general fat loss, muscle gain, anti-aging benefit, athletic recovery, or equivalent outcomes from compounded products.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval fact checks
“Tesamorelin is an approved general weight-loss drug.”
Misleading. The label specifically says it is not indicated for weight-loss management.
Applies to: The current Egrifta SV and Egrifta WR labels.
Products in this review
These are selected records, not every product or form.
Egrifta SV
- Ingredients and form
- 2 mg single-dose vial
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.
Published label: 2024 label
Read the published Egrifta SV FDA label (PDF)Egrifta WR
- Ingredients and form
- 11.6 mg single-patient-use multidose vial
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.
Published label: March 2025
Read the published Egrifta WR FDA label (PDF)What the research shows
Controlled trials in adults with HIV-associated abdominal fat accumulation found less visceral fat, which is fat around internal organs. The Egrifta SV and Egrifta WR labels say the products are not indicated for weight-loss management and that long-term cardiovascular safety has not been established. Their formulations are not substitutable.
Read all Tesamorelin fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 4 sources
- EGRIFTA SV (tesamorelin) prescribing information
U.S. Food and Drug Administration · Drug label · 2024
Source accessed
- EGRIFTA WR (tesamorelin) prescribing information
U.S. Food and Drug Administration · Drug label · 2025
Source accessed
- Tesamorelin in HIV-associated abdominal fat accumulation
PubMed · Journal of Acquired Immune Deficiency Syndromes · Randomized trial · 2010
Source accessed
- 2026 Prohibited List
World Anti-Doping Agency · Anti-doping · 2026
Source accessed